Clinical Trials Directory

Trials / Recruiting

RecruitingNCT01967511

Defining the Basis of Fibromuscular Dysplasia (FMD)

Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Icahn School of Medicine at Mount Sinai · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.

Detailed description

Specific aims * Specific aim 1: To establish a library of fibroblasts, DNA, plasma and serum from patients with FMD, SCAD and CvAD and unaffected healthy control subjects. * Specific aim 2: To perform a fully powered cross-tissue systems analysis of the key regulatory gene networks and disease drivers underlying FMD, SCAD and CvAD. * Specific aim 3: To cross-compare the molecular and genomic profiles of FMD, SCAD and CvAD to establish the degree of biologic similarity among these disorders.

Conditions

Timeline

Start date
2013-10-01
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2013-10-23
Last updated
2025-09-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01967511. Inclusion in this directory is not an endorsement.